Drugs / Y27632
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05309135 | Mar 2022 → Mar 2023 | corneal edema | Aurion Biotech | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT06041256 | Oct 2023 → Oct 2024 | corneal edema | Aurion Biotech | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT06630169 | Sep 2024 → Oct 2025 overdue | corneal edema | Aurion Biotech | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07368959 | Feb 2026 → Jun 2027 expected | Fuchs' endothelial dystrophy, bullous keratopathy | Aurion Biotech | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-10-18 | Aurion Biotech | Results Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months aurionbiotech.com ↗
At 12 months, 65% of subjects in the high-dose AURN001 group vs. 0% of the Y-27632 group achieved a ≥15-letter best corrected visual acuity (BCVA) gain (p<0.0001). |
| 2023-05-02 | Aurion Biotech | Results Aurion Biotech to Present Clinical Trial Results at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting aurionbiotech.com ↗
Escalon data are consistent with our previous trials showing clinically meaningful improvements in central corneal thickness and best corrected visual acuity. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-18 | Aurion Biotech | Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months aurionbiotech.com ↗ |
| 2023-05-02 | Aurion Biotech | Aurion Biotech to Present Clinical Trial Results at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting aurionbiotech.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y27632 | “HCEC-1 = human cultured corneal endothelial cells and Rho kinase Y-27632 inhibitor” NCT05309135 ↗ |
| Action | Inhibit | “Rho kinase Y-27632 inhibitor” NCT05309135 ↗ |
| Modality | Small molecule | — CHEMBL559147 ↗ |